Announcements
- Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
- Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
- Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
- Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
- Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
- Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
- Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
More ▼
Key statistics
On Thursday, Adaptive Biotechnologies Corp (1HM:DEU) closed at 2.95, 18.28% above the 52 week low of 2.49 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.65 |
---|---|
High | 3.08 |
Low | 2.61 |
Bid | 2.92 |
Offer | 3.04 |
Previous close | 2.69 |
Average volume | 179.50 |
---|---|
Shares outstanding | 145.09m |
Free float | 142.10m |
P/E (TTM) | -- |
Market cap | 419.32m USD |
EPS (TTM) | -1.56 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:50 BST.
More ▼